United States securities and exchange commission logo May 11, 2023 Ross Muken Chief Financial Officer SOPHiA GENETICS SA 185 Dartmouth Street Floor 5 Boston, MA 02116 Re: SOPHiA GENETICS SA Form 20-F for the Fiscal Year Ended December 31, 2022 Filed March 7, 2023 Form 6-K furnished May 9, 2023 File No. 001-40627 Dear Ross Muken: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Form 6-K furnished May 9, 2023 Exhibit 99.3 Reconciliation of IFRS to Adjusted IFRS Statement of Profit and Loss, page 11 1. Your non-IFRS presentation appears to represent a full consolidated statement of profit and loss. Please tell us why you believe your presentation is consistent with Question 102.10(a) through (c) of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures. Ross Muken FirstName LastNameRoss SOPHiA GENETICS SA Muken Comapany May NameSOPHiA GENETICS SA 11, 2023 May 11, Page 2 2023 Page 2 FirstName LastName In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Mary Mast at (202) 551-3613 or Frank Wyman at (202) 551-3660 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences